In patient #3, CRISPR-edited CD3– CART cells did not re-expand probably because the relapsing tumor cells lost antigen expression, as suggested by the aberrant increase of urea κ LC with low levels of IgA (Fig. 4d) and no detection of BCMA+ cells in peripheral blood (Fig. 5c). Here, CD79A is linked to neoplasm.